SAN FRANCISCO—Histotripsy for liver tumors, a noninvasive, non-ionizing and nonthermal therapy approved by the FDA for this indication in 2023, that uses ultrasound waves to locally destroy cancerous tissue, demonstrated a promising safety profile in a study presented at the 2024 Clinical Congress of the American College of Surgeons. The study is the first report on liver histotripsy for liver tumors in real practice.
The investigators collected data on safety outcomes